{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-059252","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2025-06-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.432648+00:00","generated_at":"2026-05-18T13:25:55.408205+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"INmune Bio Phase 2 MINDFuL trial misses primary endpoint; positive subgroup data in inflammation-biomarker AD patients","bullets":["Primary cognitive endpoint EMACC not met in mITT (n=200); predefined subgroup with ≥2 inflammation biomarkers (n=100) showed cognitive benefit (effect size 0.27).","In same subgroup, behavioral benefit on NPI (effect size -0.24) and biological benefit on pTau217 (effect size -0.20).","XPro well-tolerated; no ARIA-E or ARIA-H; injection site reactions common (80% XPro vs <20% placebo).","Company to file for Breakthrough Therapy designation; End-of-Phase 2 meeting with FDA scheduled for Q4 2025.","Additional MINDFuL analyses to be presented at AAIC in Toronto, July 27-31, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-059252","json":"https://secwatch.observer/filing/0001213900-25-059252.json","markdown":"https://secwatch.observer/filing/0001213900-25-059252.md","text":"https://secwatch.observer/filing/0001213900-25-059252.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025059252/0001213900-25-059252-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025059252/ea0247460-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T13:25:55.408205+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}